Viridian Secures Commercial Manufacturing for Veligrotug Ahead of PDUFA Date
VRDN sits 29% above its 52-week low of $13.18.
Summary
Viridian Therapeutics has entered into a commercial manufacturing agreement with WuXi Biologics for its drug candidate, veligrotug, in preparation for potential market approval.
Key Events · Product Development and Regulatory · VRDN
-
Commercial Manufacturing Agreement
Viridian Therapeutics signed a non-exclusive Commercial Manufacturing Services Agreement with WuXi Biologics for the long-term supply of veligrotug drug substance and drug product for commercial use, if approved.
-
Preparation for Commercial Launch
This agreement is a key step in preparing for the potential commercialization of veligrotug, which has a PDUFA target action date of June 30, 2026.
-
Agreement Terms
The agreement has an initial term of five years, with automatic five-year renewals, and includes volume-based pricing with fixed fees until December 31, 2026.
Analysis · VRDN · Life Sciences
This agreement with WuXi Biologics is a critical step for Viridian Therapeutics, ensuring a long-term supply chain for veligrotug drug substance and product. With a PDUFA target action date of June 30, 2026, this manufacturing deal de-risks the commercial launch process, demonstrating the company's readiness to bring the drug to market if approved. It signals operational progress and confidence in the drug's potential.
At the time of this filing, VRDN was trading at $17.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $13.18 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.